Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with a capital raising
Mandate

Vinge advises Cinclus Pharma in connection with a capital raising

March 05, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Related

Vinge represents Triton in connection with the sale of Aleris

 Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026

Vinge advises L5 Navigation in connection with the acquisition of Lundaman Instrument

 L5 Navigation Systems AB has acquired the shares in Lundaman Instrument AB. Lundaman develops and supplies weighing systems for wheel loaders and forklift trucks, focusing on the construction, recycling, industrial and materials handling sectors.
May 13, 2026

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

 Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026